
    
        <!DOCTYPE html>
        <html lang="hu-HU" data-website-id="1" data-oe-company-name="HBS Medical">
            
<!-- Mirrored from hbs.hu/slides/slide/treatment-of-interstitial-cystitis-in-women-49 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:22:26 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
                <meta charset="utf-8"/>
                <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
                <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no"/>

                <title>Treatment of interstitial cystitis in women!!! | HBS</title>
                <link type="image/x-icon" rel="shortcut icon" href="../../web/image/website/1/favicon/index.html"/>

                <script type="text/javascript">
                    var odoo = {
                        csrf_token: "f2e9a41588799d043a772b21ddc3189150ea199fo",
                    };
                </script>

                
            <meta name="generator" content="Odoo"/>

            
            
            
            
            
            
                
                
                
                    
                        <meta property="og:type" content="website"/>
                    
                        <meta property="og:title" content="Treatment of interstitial cystitis in women!!!"/>
                    
                        <meta property="og:site_name" content="HBS Medical"/>
                    
                        <meta property="og:url" content="https://hbs.hu/slides/slide/treatment-of-interstitial-cystitis-in-women-49"/>
                    
                        <meta property="og:image" content="https://hbs.hu/web/image/slide.slide/49/image_thumb"/>
                    
                        <meta property="og:description"/>
                    
                
                
                
                    
                        <meta name="twitter:card" content="summary_large_image"/>
                    
                        <meta name="twitter:title" content="Treatment of interstitial cystitis in women!!!"/>
                    
                        <meta name="twitter:image" content="https://hbs.hu/web/image/slide.slide/49/image_thumb"/>
                    
                        <meta name="twitter:description"/>
                    
                
            

            
            
                
                    <link rel="alternate" hreflang="hu" href="treatment-of-interstitial-cystitis-in-women-49.html"/>
                
            

            <script type="text/javascript">
                odoo.session_info = {
                    is_admin: false,
                    is_system: false,
                    is_frontend: true,
                    translationURL: '/website/translations',
                    is_website_user: true,
                    user_id: 4
                };
                
            </script>

            <link type="text/css" rel="stylesheet" href="../../web/content/521-3ab7b2c/1/web.assets_common.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/599-e81acc7/1/web.assets_frontend.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/600-e81acc7/1/web.assets_frontend.1.css"/>
            
            
            

            <script type="text/javascript" src="../../web/content/524-3ab7b2c/1/web.assets_common.js"></script>
            <script type="text/javascript" src="../../web/content/603-e81acc7/1/web.assets_frontend.js"></script>
            
            
            
        
            </head>
            <body>
                
            
        
            
        
        
            
                
                    
                
                
            
        
        
    
    

            
            
        
    
            
          
        <link rel="stylesheet" type="text/css" href="../../sh_cookie_notice/static/src/css/cookieconsent.min.css"/>
        <script type="text/javascript" src="../../sh_cookie_notice/static/src/js/cookieconsent.min.js"></script>
        

	
	<script type="text/javascript"> 

	 window.addEventListener("load", function(){
 
	var sh_msg = String("Az HBS weboldala sütiket használ a weboldal működtetése, használatának megkönnyítése, a weboldalon végzett tevékenység nyomon követése és releváns ajánlatok megjelenítése érdekében.");
	var sh_esc_msg = encodeURIComponent(sh_msg);
	sh_esc_msg = decodeURIComponent(sh_esc_msg); 
	
  	window.cookieconsent.initialise({
	  "palette": {
	    "popup": {
	      "background": "#000" 
	    },
	    "button": {
	      "background": "#f1d600"
	    }
	  },
	  
	  	  "position": "top",
	  
	
	  
	  "content": {
	    "message": sh_esc_msg,
	    "dismiss": "Elfogadom",
	    "allow": "allow",
	    "link": "Adatvédelmi tájékoztató",
	    "href": "/adatkezelesi-tajekoztato"
	  }
	})});
    </script>
 
   
    <div id="wrapwrap" class="   ">
                <header class=" o_affix_enabled">
                    <nav class="navbar navbar-expand-md navbar-light bg-light">
                        <div class="container">
                            <a href="../../index.html" class="navbar-brand logo">
            <span role="img" aria-label="Logo of HBS Medical" title="HBS Medical"><img src="../../web/image/res.company/1/logo66cf.png?unique=866a03a" class="img img-fluid"/></span>
        </a>
    <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#top_menu_collapse">
                                <span class="navbar-toggler-icon"></span>
                            </button>
                            <div class="collapse navbar-collapse" id="top_menu_collapse">
                                <ul class="nav navbar-nav ml-auto text-right o_menu_loading" id="top_menu">
                                    
        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../index.html" class="nav-link ">
            <span>HBS Medical</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../../covid-19.hbs.hu/index.html" class="nav-link " target="_blank">
            <span>COVID-19</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../blog/hirek-esemenyek-1.html" class="nav-link ">
            <span>Hírek</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../aboutus.html" class="nav-link ">
            <span>Kapcsolat</span>
        </a>
    </li>
    

        
    
                                    
                                </ul>
                            </div>
                        </div>
                    </nav>
                </header>
                <main>
                    
        
        <div class="container mt16">
            <div class="row">
                <div class="col-xl-8 col-lg-8 col-md-12 col-12">
                    

                    <div>
                            
                        <div class="embed-responsive embed-responsive-4by3 embed-responsive-item mb8">
                            <iframe src="../embed/492679.html?page=1" class="o_wslides_iframe_viewer" allowFullScreen="true" height="315" width="420" frameborder="0"></iframe>
                        </div>
                        
                        <div class="row">
                            <h4 class="col-lg-6">Treatment of interstitial cystitis in women!!!</h4>
                            <div class="col-lg-6">
                                <div clas="row">
                                    
                                </div>
                            </div>
                        </div>
                        <div class="row">
                            <div class="col-md-8 col-12">
                                <div class="float-left">
                                    <a href="../nyilvanos-anyagok-1.html" title="Channel Nyilvános anyagok" aria-label="Channel Nyilvános anyagok">
                                        <i class="fa fa-circle-o fa-5x" style="color: #875A7B;font-weight: bold;"></i>
                                    </a>
                                </div>
                                <div style="margin-left: 80px">
                                    <p>
                                        <a href="../nyilvanos-anyagok-1.html">Nyilvános anyagok</a>
                                        
                                            <span> / </span>
                                            <a href="../nyilvanos-anyagok-1/category/szakirodalmi-cikkek-3.html">Szakirodalmi cikkek</a>
                                        
                                    </p>
                                    <div>
                                        
        <div class="input-group js_follow" data-id="1" data-object="slide.channel" data-follow="off">
            <input type="email" name="email" class="js_follow_email form-control" placeholder="emailje..."/>
            <div class="input-group-append">
                <button href="#" class="btn btn-secondary js_unfollow_btn">Leiratkozás</button>
                <button href="#" class="btn btn-primary js_follow_btn">Feliratkozás</button>
            </div>
        </div>
    
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-4 d-none d-md-block">
                                <div class="text-right">
                                    <b class="h3 text-muted">1190</b> <span class="text-muted small">views</span>
                                </div>
                                
                                <div class="progress mb0" style="height: 2px;">
                                    <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" style="width: 0%;">
                                        <span class="sr-only">0 Likes</span>
                                    </div>
                                </div>
                                <div class="text-muted mt4">
                                    <div class="float-right mb16 text-right">
                                        <span class="oe_slide_js_like" data-href="/slides/slide/like" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="49">
                                            <i class="fa fa-thumbs-up fa-1x" role="img" aria-label="Likes" title="Likes"></i>
                                            0
                                        </span>
                                        <span class="oe_slide_js_unlike" data-href="/slides/slide/dislike" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="49">
                                            <i class="fa fa-thumbs-down fa-1x" role="img" aria-label="Dislikes" title="Dislikes"></i>
                                            0
                                        </span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="mt8 mb32">
                            <ul class="nav nav-tabs" role="tablist">
                                <li class="nav-item">
                                    <a href="#about" aria-controls="about" role="tab" data-toggle="tab" class="nav-link active">
                                        <i class="fa fa-home"></i> About
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#share" aria-controls="share" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-share-alt"></i> Share
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#discuss" aria-controls="discuss" role="tab" data-toggle="tab" class="nav-link">
                                        <i class="fa fa-comments-o"></i> Comments
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#transcript" aria-controls="transcript" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-align-justify"></i> Transcript
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#statistic" aria-controls="statistic" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-bar-chart"></i> Statistics
                                    </a>
                                </li>
                            </ul>
                            <div class="tab-content" style="padding: 20px 5px 5px 5px; word-wrap: break-word;">
                                <div role="tabpanel" id="about" class="tab-pane fade active in">
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="share">
                                    
    <h4 class="mt0">Share on Social Networks</h4>
    
    <div>
        <a class="o_slides_social_share" social-key="facebook" aria-label="Share on Facebook" title="Share on Facebook" href="https://www.facebook.com/sharer/sharer.php?u=https://hbs.hu/r/js2"><i class="fa fa-facebook-square fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="twitter" aria-label="Share on Twitter" title="Share on Twitter" href="https://twitter.com/intent/tweet?text=Treatment%20of%20interstitial%20cystitis%20in%20women!!!&amp;url=https://hbs.hu/r/js2"><i class="fa fa-twitter fa-2x"></i></a>
        <a social-key="linkedin" class="o_slides_social_share" aria-label="Share on LinkedIn" title="Share on LinkedIn" href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://hbs.hu/r/js2&amp;title=Treatment%20of%20interstitial%20cystitis%20in%20women!!!&amp;"><i class="fa fa-linkedin fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="gplus" aria-label="Share on Google Plus" title="Share on Google Plus" href="https://plus.google.com/share?url=https://hbs.hu/r/js2"><i class="fa fa-google-plus-square fa-2x"></i></a>
    </div>

    <h4 class="mt-3">Share Link</h4>
    <input type="text" class="form-control" readonly="readonly" onClick="this.select();" value="treatment-of-interstitial-cystitis-in-women-49.html"/>
    <span class="form-text">Use permanent link to share in social media</span>

                                    
    <h4 class="mt-3">Share with a friend</h4>
    
    
        <p>Please <a href="../../web/login.html?redirect=https://hbs.hu/slides/slide/treatment-of-interstitial-cystitis-in-women-49"> login </a> to send this document by email!</p>
    

                                    
                                        
    <div class="oe_slide_js_embed_code_widget">
        <h4 class="mt0">Embed in your website</h4>
        <div class="form-group">
            <textarea class="form-control slide_embed_code" readonly="readonly" onClick="this.select();">&lt;iframe src=&quot;https://hbs.hu/slides/embed/49?page=1&quot; class=&quot;o_wslides_iframe_viewer&quot; allowFullScreen=&quot;true&quot; height=&quot;315&quot; width=&quot;420&quot; frameborder=&quot;0&quot;&gt;&lt;/iframe&gt;</textarea>
        </div>
        <div class="form-group">
            <div class="form-text col-xl-3 col-lg-3 col-md-6 col-6">Select page to start with</div>
            <div class="input-group col-xl-3 col-lg-3 col-md-6 col-6">
                <input type="number" value="1" class="form-control"/>
            </div>
        </div>
    </div>

                                    
                                </div>
                                
                                <div role="tabpanel" id="discuss" class="tab-pane fade">
                                    
        <div id="discussion" class="d-print-none o_portal_chatter o_not_editable p-0" data-res_model="slide.slide" data-res_id="49" data-pager_step="10" data-allow_composer="1">
        </div>
    
                                </div>
                                <div role="tabpanel" class="tab-pane fade oe_slides_transcript" id="transcript">
                                    
                                        
                                            <p>2. Conservative treatment Treatment strategies for IC should begin from more conservative therapies, and initial treatment type should depend on patient preferences, symptom severity, and the clinician’s decision-making. The available conservative ther- apeutic options for treating IC are numerous, and include behavior therapy, dietary control, stress reduction, and phys- ical therapy. Behavioral therapy including bladder training, controlled fluid intake, and Kegel exercises improved symptoms in more than one-half of the IC patients [7,8] . IC patients afflicted with the chronic form of this disease will usually have a reduced-capacity bladder that is in part based on their constant urination at low volumes. The bladder holding protocol dictates keeping a voiding diary, carefully timing voiding, and gradually increasing the intervals between voiding. This behavior modification may be helpful in increasing bladder capacity. Although controlled studies regarding the effect of dietary manipulation on IC are lacking, diet control is recommended as a first-line self-care treatment regimen for IC patients. More than 50% of IC patients can identify acidic foods that aggra- vate or cause a relapse in symptoms [9] . Dietary manipulation by avoiding acidic beverages, caffeine, alcohol, chocolate, tea, soda, spicy food, and artificial sweetener may be helpful [10,11] . Once offending foods are suspected, the use of an elimination  diet  might  identify  which  foods  or  fluids contribute to flare symptoms, and the patient should then be counseled to avoid said foods [12,13] . However, not all patients need to try a restricted diet, and not every patient is sensitive to the same foods. Because many IC patients modify their diet and are also chronically ill, nutritional supplemen- tation can be of benefit [10] . Stress is likely the most significant factor that aggravates the symptoms of IC. Patients should be encouraged to implement stress reduction techniques. The techniques might not only be very useful preventative management for patients in remission but also beneficial to patients with severe symptoms. For those with severe symptoms, stress reductions such as lifestyle changes, shortening working hours, choosing a less demanding workload, exercise, bathing, or joining support groups could be exceedingly helpful [9,14,15] .In addition, because psychological and emotional support from the family is crucial, patient education is necessary to give the patient and her family a good understanding of IC to help cope with the disease. Working against such stress reduction interventions are the stress-creating IC symptoms such as chronic bladder pain (or pelvic pain), urinary frequency, and sleep loss due to nocturia. These can cause anxiety and depression. Remission of these IC symptoms can help to reduce patient stress. Physical therapy such as exercising regularly, learning self- relaxation of the pelvic floor muscles, using biofeedback, and using maneuvers that resolve pelvic or other connective tissue pains can help; one can also try the more mental techniques such  as  learning  meditation [16 e 18] .  Other  adjuvant treatments reported to relieve IC symptoms include acupunc- ture, hypnosis, and soft tissue massage [19] . However, pelvic floor  strengthening  exercises,  including  Kegel  exercises, should be avoided [20] . Oral medication Oral pharmacologic therapies remain a mainstay for the treatment of IC. Oral medications include pentosan polysulfate sodium (PPS), amitriptyline (Elavil), hydroxyzine (Atarax), antimuscarinics, cyclosporine A (Cy A), antibacterial agents, and analgesics. To date, clinical trials of individual therapies with oral medication have been limited in terms of size, quality, and duration of follow-up, and studies of combination or multimodal therapies are lacking [6] . PPS (Elmiron) is the only oral therapy with U.S. Food and Drug Administration approval for the treatment of IC. The etiology of IC remains unclear; however, the most frequently discussed pathologic abnormality used to explain IC is a defect of the epithelial glycosaminoglycan (GAG) layer that separates and protects the transitional epithelium from urine [21] . PPS, a weak heparinoid similar to one of the components in the GAG layer, is believed to repair the damaged GAG layer and prevents leakage in the urothelium. It is the first oral medication for IC that has undergone randomized placebo- controlled  trials [22 e 25] .  Three  trials  showed  modest symptom improvement [26 e 28] . However, the results of the placebo-controlled  double-blind  trials  are  contradictory [23,24,28] . This implies that some IC patients may have urothelial leakage, but not all IC is due to GAG layer deficiencies. Chronic pelvic pain and sleep disturbances may cause stress in IC patients. Amitriptyline, a tricyclic antidepressant used to relieve the chronic pain associated with IC, may also have an effect on sleep disturbances because of its antihista- mine  sedation  effects,  and  thus  improve  nocturia.  van Ophoven et al [29] showed that amitriptyline provided symptomatic relief for 15 out of 24 patients in one RCT. However, the trial did not compare to placebo. Amitriptyline at different dosages showed a large effect size on standardized means of pain and urgency scales and on O’Leary e Sant Interstitial Cystitis Symptom Index and frequency [30] . The patients treated with this medication, starting at 10 to 25 mg daily, should be given increased dosages to increase the effect as long as the side effects, including dry mouth and drowsi- ness, remain tolerable. Long-term administration of amitrip- tyline is a feasible, safe, and effective treatment for IC provided that the drug is used judiciously to minimize adverse effects [31] . Hydroxyzine, a Hi-blocker, involves the theory of pre- venting mast cell degranulation with the release of neuroactive and vasoactive chemicals. However, in one RCT, hydroxyzine failed to show statistically significant benefits over placebo [32] .  In  addition,  although  the  combination  with  PPS demonstrated a tendency toward a significant effect for the treatment of IC, there was still no statistical difference in efficacy as compared with placebo. 527 C.-H. Hsieh et al. / Taiwanese Journal of Obstetrics &amp; Gynecology 51 (2012) 526 e 532 </p>
                                        
                                            <p>3. Antimuscarinics have been used to treat overactive blad- ders. There is a significant overlap between an overactive bladder and IC symptoms. Nevertheless, the efficacy of anti- muscarinics for IC patients could be limited because the pathophysiology of IC and overactive bladder might be diversely different even if the symptoms overlap. Cy A is a calcineurin inhibitor that inhibits T cell activation by blocking the transcription of cytokine genes, among other functions [33] . Cy A also stabilizes mast cells [34] . Thus, Cy A is a potent inhibitor of the immune system, and its efficacy has been reported in the treatment of IC patients [35] .In a prospective randomized study, Sairanen et al [36] showed that Cy A is more effective than PPS for the treatment of IC (with response rates of 75% and 19% for Cy A and PPS, respectively). However, there were more adverse events in the Cy A arm than in the PPS arm. Antibacterial agents are not recommended for the treatment of IC. In a randomized placebo-controlled study, oral antibi- otics were shown to have no statistically significant thera- peutic effect over placebo, and adverse effects occurred more often in the antibiotics arm [37] . Pain is probably the most frequent driving symptom for an IC patient to void at lower voiding volume. Low-potency nonste- roidal anti-inflammatory drugs (NSAIDs) can be used as first- line analgesics. Other drugs that may be useful are more potent NSAIDs, cyclooxygenase-2 selective drugs, phenazo- pyridine(Pyridium), oxybutyninchloride(Ditropan), or opioids. The use of opioids in urogenital pain is poorly defined. Inter- esting drugs that are potentially useful in controlling bladder pain include cannabinoid receptor agonists and purinergic receptor antagonist compounds. It is important to note that pain management alone is not considered to be sufficient treatment for IC and that pain management is just one part of treatment. Intravesical therapy Bladder instillation with different agents for the treatment of IC has been used for decades. The mechanism for this comprises the existing theories about urothelial dysfunction. Intravesical pharmacotherapy is one of the mainstays in the treatment of IC. Intravesical therapy allows the administration of medication directly into the bladder and achieves a high drug concentration in the bladder. It also provides a potential low incidence of systemic side effects due to the relatively poor absorption from the bladder, provided that the time that the agent is kept in the bladder is short. Intravesical therapy could also eliminate the problem of low concentration of urinary excretion by oral medications and directly target the urothelium if the pathophysiology of IC is directly related to urothelial abnormalities. The drugs available for intravesical therapy are used singly or as a mixture of multiple medications (as a cocktail). The most commonly used agents include dimethyl sulfoxide (DMSO), heparin, hyaluronic acid, lido- caine, PPS, oxybutynin, chondroitin sulfate, steroid, and other agents mixed as a cocktail. Overall, the evidence base for treating IC using intravesical preparations is limited, and RCTs for the treatment of IC are still needed [38] . DMSO may be the most commonly used intravesical agent for IC, and it is the only intravesical therapy since 1978 with U.S. Food and Drug Administration approval for the treatment of IC. The mechanism of DMSO is not clear but it supposedly has an anti-inflammatory effect. The drug is also claimed to work as an analgesic, as a muscle relaxant, and to promote collagenolysis. The dose of DMSO used intravesically is 50 mL of a 50% solution instilled into and retained in the bladder for 10 to 20 minutes, given from one to two times a week to every few months. In a randomized double-blind placebo-controll ed study, Perez-Marrero et al [39] showed a marked improvement of symptoms in 53% of DMSO-treated patients. In a recent study, Rossberger et al [40] reported that intravesical instillation therapy with DMSO appears to be a feasible treatment option for both subtypes of IC with the effect lasting 16 e 72 months and is associated with a reasonably low degree of discomfort. Additional treatments for the relapsed patients would be needed. Heparin, an anionic polyelectrolyte, is a GAG derivative. Intravesical heparin, in a dose of 10,000 e 20,000 IU in 2 e 5 mL of solution introduced intravesically for a duration of 1 hour, thrice a week, is used because of the putative GAG layer deficiency in IC. Parsons et al [41] showed that 56% of IC patients had their symptoms relieved by heparin. However, the evidence for intravesical heparin for IC patients is still limited, and RCTs for the treatment are needed. Hyaluronic acid, a glycoprotein, is the traditional agent used for GAG substitution. Several studies have shown that hyaluronic acid has a place in the treatment for IC with comparable efficiency and without significant toxicity [42 e 44] . In a prospective study recently, Van Agt et al [45] treated the patients by administration of 40 mg (50 mL) intravesical hyaluronic acid three times weekly and obtained a positive response rate of 52% after 6 weeks of treatment. Intravesical lidocaine (1%), usually 20 e 30 mL, may be used. A case report revealed that bladder pain and frequency could be controlled, but symptoms recurred within 3 months after treatment [46] . Other studies also reported that lidocaine instillation relieved pain for only a short term [47,48] . PPS has been administered intravesically and has been indicated to be effective. Pilot studies suggest a therapeutic benefit and with earlier responses than those observed with oral PPS [49] . The use of intravesical PPS simultaneously with oral PPS has been proposed to be a safe and effective thera- peutic option [50] . These findings of Davis et al [50] might open a new option for patients with IC to reduce their symptom severity and to improve their QOL. In a randomized trial of intravesical administration of oxybutynin in combination with bladder training versus placebo instillation plus bladder training, the oxybutynin group had a significant increase in bladder capacity, decrease in urinary frequency, pain relief, and did not have adverse events [51] . Cho ndroitin sulfate, a glycoprotein, is a major component of the GAG layer. GAG layer replenishment is a cornerstone in 528 C.-H. Hsieh et al. / Taiwanese Journal of Obstetrics &amp; Gynecology 51 (2012) 526 e 532 </p>
                                        
                                            <p>7. [79] Nielsen KK, Kromann-Andersen B, Steven K, Hald T. Failure of combined supratrigonal cystectomy and Mainz ileocecocystoplasty in intractable interstitial cystitis: is histology and mast cell count a reliable predictor for the outcome of surgery? J Urol 1990;144: 255 e 8. [80] Kontturi MJ, Hellstrom PA, Tammela TL, Lukkarinen OA. Colocystoplasty for the treatment of severe interstitial cystitis. Urol Int 1991;46:50 e 4. [81] Irwin PP, Galloway NT. Surgical management of interstitial cystitis. Urol Clin North Am 1994;21:145 e 51. [82] Linn JF, Hohenfellner M, Roth S, Dahms SE, Stein R, Hertle L, et al. Treatment of interstitial cystitis: comparison of subtrigonal and supra- tigonal cystectomy combined with orthotopic bladder substitution. J Urol 1998;159:774 e 8. [83] Peeker R, Aldenborg F, Fall M. The treatment of interstitial cystitis with supratrigonal cystectomy and ileocystoplasty: difference in outcome between classic and nonulcer disease. J Urol 1998;159:1479 e 82. [84] van Ophoven A, Oberpenning F, Hertle L. Long-term results of trigone- preserving  orthotopic  substitution  enterocystoplasty  for  interstitial cystitis. J Urol 2002;167:603 e 7. [85] Rossberger J, Fall M, Jonsson O, Peeker R. Long-term results of reconstructive surgery in patients with bladder pain syndrome/interstitial cystitis: subtyping is imperative. Urology 2007;70:638 e 42. [86] Andersen AV, Granlund P, Schultz A, Talseth T, Hedlund H, Frich L. Long-term experience with surgical treatment of selected patients with bladder pain syndrome/interstitial cystitis. Scand J Urol Nephrol 2012; 46:284 e 9. 532 C.-H. Hsieh et al. / Taiwanese Journal of Obstetrics &amp; Gynecology 51 (2012) 526 e 532 </p>
                                        
                                            <p>4. the treatment of IC. A review of GAG layer intravesical replenishment therapy for IC in the small number of RCTs so far confirms that chondroitin sulfate (0.2%) is favorable for intravesical GAG layer replenishment therapy [52] . However, large-scale trials are urgently needed to further define the benefit of this type of therapy. Corticotherapy can be given intravesically because of its anti-inflammatory effects, and bladder inflammation has been noted in some patients with IC [53] . Methylprednisolone, from 500 mg to 1 g, can be reconstituted in a small volume of liquid (10 e 15 mL) and mixed with DMSO. Bladder instillation with different agents has been used for years in an attempt to treat IC. These agents are usually mixed as a cocktail because there are varying degrees of success for each drug. The selection of the regimen up to the present has mainly been based on empiricism. Patients usually undergo one treatment per week for a 6-week period once the treatment starts, and the maintenance schedule of treatment depends on the responses of patients [53] . Other agents that have been used for intravesical treatment of IC include silver nitrate, Clorpactin, cromolyn sodium, sodium  bicarbonate,  resiniferatoxin,  and  Bacillus  Calm- ette e Guerin (BCG) vaccine. However, resiniferatoxin and BCG should not be offered to patients because the two drugs did not show efficacy in well-controlled trials [54,55] . Finally, the antiproliferative factor protein might be an important therapeutic target in the future because it might also have an important role as a urine marker for IC [56] . Intravesical botulinum toxin A injection Botulinum toxin A, an inhibitor of acetylcholine release at the presynapse of neuromuscular junction, has well-known analgesic properties and has demonstrated some benefits in treating IC pain. The agent has been proved effective for refractory IC in an open, exploratory study [57] . There are also several studies that indicated symptom relief in the treatment of IC with intravesical botulinum toxin A injection, single or repeated, and did not have significant adverse events [58 e 62] , However, evidence for botulinum toxin A in the treatment of IC is limited to small case series. In addition, a systematic review of reports on the agent for the treatment of IC concludes that the evidence from the studies so far suggests a trend toward short-term benefit in refractory patients, but also noted that further robust evidence should be awaited [63] . Hydrodistention HD is recommended for the treatment of IC. The efficacy of HD of the bladder in the treatment of IC has been known since the first report appeared in 1930 [64] . Although the therapy has been the most common treatment for IC since then, there has been no randomized comparative study. The proportion of patients who, after bladder HD, show improve- ment and the duration of any such improvement remain uncertain. The report by Bumpus [64] in 1930 showed that HD improved the symptoms of IC and, as a result, this procedure has become a mainstay of IC patients’ therapy. Most reports showed that IC symptoms in patients are improved following HD, but they suggest that the benefits are short-lived [65 e 68] . Furthermore, a study reported that HD provided little useful information above and beyond what was available from the patient’s history and physical examination findings [69] .In addition, reports on the use of prolonged bladder HD for the treatment of patients with IC remain controversial [70,71] . Nevertheless, Hsieh et al [72] showed that HD followed by bladder training, when there was good patient compliance, was able to produce both a good efficacy and long-term benefits [72] . There is no standard method for HD, nor is there a significant difference in efficacy among current HD methods. The safest method is to fill the bladder with normal saline to maximal capacity at a pressure of 80 cm H 2 O, at which point the full bladder is emptied immediately, without repetition of the procedure. Bladder rupture and sepsis may be associated with HD, especially when high-pressure, long-duration HD has been offered [66,70,71] . Surgery The role of major surgery in patients with IC is not fully established. Surgical intervention is not a mainstay in the treatment of IC symptoms and should be considered the last resort for severe IC refractory to other therapies. Before surgery, the patient should be informed of all surgical proce- dures and should understand the possible outcomes and possible side effects of this type of intervention. Less invasive surgeries to treat IC include sacral neuro- modulation to control the symptoms of IC. Sacral neuro- modulation should be considered before any major invasive surgical intervention is undertaken and after conservative therapies have failed. Several retrospective studies indicate that sacral neuromodulation provides an effective long-term outcome [73 e 76] .  The  use  of  the  neodymium e yttrium aluminum garnet (YAG) laser to fulgurate Hunner’s ulcers to alleviate IC symptoms has been reported; however, repeated treatment is usually required [77,78] . The major surgical interventions that have been described to treat IC include bladder augmentation, urinary diversion, and cystectomy [79 e 86] . Although some studies have re- ported that major surgery is associated with good symptom relief in strictly selected patients with disabling IC, surgical intervention for IC has been demonstrated to be of limited use and failed to achieve long-term remission of symptoms in the majority of patients. Conclusion IC is a complex disease with a constellation of symptoms such as urinary urgency, urinary frequency, and pelvic pain affecting urine storage in the bladder. Many physicians still do not believe that IC exists because IC remains a mysterious syndrome in female urology. In addition, limited evidence exists for the few IC treatment options available to doctors. 529 C.-H. Hsieh et al. / Taiwanese Journal of Obstetrics &amp; Gynecology 51 (2012) 526 e 532 </p>
                                        
                                            <p>1. Review Article Treatment of interstitial cystitis in women Ching-Hung Hsieh a , b , * , Wei-Chun Chang c , Ming-Chao Huang d , Tsung-Hsien Su d , Yiu-Tai Li e , Han-Sun Chiang b a Department of Obstetrics and Gynecology, Clinic of Fu Jen Catholic University, Taipei, Taiwan b School of Medicine, Fu Jen Catholic University, Taipei, Taiwan c Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan d Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan e Department of Obstetrics and Gynecology, Kuo General Hospital, Tainan, Taiwan Accepted 14 September 2012 Abstract Interstitial cystitis (IC) has been described as a chronic debilitating sterile inflammatory multifactorial bladder syndrome of unknown etiology. IC is characterized by bladder pain (or suprapubic pain) associated with urgency, urinary frequency, and nocturia. Because the pathogenesis of IC remains unclear, it is still an enigma and represents a diagnostic and therapeutic challenge. The diagnosis of IC remains unclear and is based on exclusion of other diseases. Consequently, IC has usually been underdiagnosed, and the consensus on best available treatment for the disease is lacking. The current goal for the treatment of IC is usually symptomatic relief, and treatment protocols are based on empiricism. Multiple forms of therapy are available, and most patients can be managed conservatively. Nevertheless, the efficacy of most treatments is short term. This review article gives an overview of the available treatments for IC. Copyright Ó 2012, Taiwan Association of Obstetrics &amp; Gynecology. Published by Elsevier Taiwan LLC. All rights reserved. Keywords: bladder training; hydrodistention; interstitial cystitis; lower urinary tract symptoms; nocturia; painful bladder syndrome; urgency; urinary frequency Introduction Interstitial cystitis (IC) has been described as a chronic debilitating sterile inflammatory multifactorial bladder disease that results in severe impairment of quality of life (QOL). It is characterized by bladder pain, urinary frequency, urgency, and nocturia. In an epidemiologic study in Finland, the prevalence of IC was estimated to be 18.1 per 100,000 women [1] . Temml et al [2] considered women with high symptom and problem scores (  12) on the O’Leary e Sant IC questionnaire [3] to be most likely to have IC. The Temml study revealed the overall prevalence of IC to be 306/100,000 women, with the highest value (464/100,000) in middle-aged women (40 e 59 years). About two-thirds of women with moderate to high risk for IC reported an impairment of QOL. In addition, the same study also showed that 35% of the IC patients reported an effect on their sexual life. However, the etiology of IC has not yet been clarified. Hence, IC has usually been underdiagnosed [4] , and the consensus on best available treatment for this condition is lacking [5] . Treatment options for IC include conservative treatments, oral medications, intravesical therapy, intravesical botulinum toxin A injection, hydrodistention (HD), and surgeries. Oral or intravesical therapies are the mainstay treatment, whereas surgical managements are reserved for refractory cases. To date, clinical trials of individual therapies for IC have been limited in terms of size, quality, and duration of follow-up [6] . In addition, studies of combination or multimodal therapies are lacking. Owing to the paucity of randomized controlled trials (RCTs) on different treatments, an evidence-based management protocol has not yet been developed. This article therefore gives an overview of the treatments for IC in women. * Corresponding author. Department of Obstetrics and Gynecology, Fu Jen Catholic University, P.O. Box 30-387, Taipei 100, Taiwan. E-mail address: <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="89fceea7ede6eac9e4fae8a7e1e0e7ecfda7e7ecfd">[email&#160;protected]</a> (C.-H. Hsieh). Available  online  at www.sciencedirect.com Taiwanese Journal of Obstetrics &amp; Gynecology 51 (2012) 526 e 532 www.tjog-online.com 1028-4559/$ - see front matter Copyright Ó 2012, Taiwan Association of Obstetrics &amp; Gynecology. Published by Elsevier Taiwan LLC. All rights reserved. http://dx.doi.org/10.1016/j.tjog.2012.10.002 </p>
                                        
                                            <p>5. However, IC is indeed a chronic, debilitating disease for the patient. Patients should first be encouraged to implement stress management practice to manage and to cope with symptom exacerbations induced by stress. Because the etiology of IC is thought to be multifactorial, multimodal therapies might be considered if the initial treat- ment does not result in a significant remission of symptoms. In addition, the predisposing etiologies inducing the development of IC should all be ruled out. In women, uterine prolapse may cause bladder compression, and the long-term effect of the pathophysiology of uterus e bladder compression may result in a reduced-capacity bladder. Furthermore, the bladder may enter a status of disuse and atrophy. The famous words “use or disuse” by La March, a French biologist (1744 e 1829), may help to explain the reduced bladder capacity of IC patients. Hence, it is important to first help reconstruct the pelvis, especially with uterine suspension when uterine prolapse has occurred, before the bladder problems in IC patients are treated. The “gold standard” IC treatment of cystoscopy with HD is now being questioned. However, the majority of reports about HD for IC patients revealed a short-term effect. This fact reveals that HD is a good method to enlarge the bladder, but IC patients could not keep their enlarged bladder for a long time after treatment. Bladder training may be an option to help post-HD IC patients to reverse their bladder from a state of disuse/atrophy into a functional state and to create a bladder big enough to obtain a long-term effect [72] . The theory about HD plus bladder training keeping the bladder large for the long term is similar to consciously sitting up straight in order to correct one’s posture. The simultaneous implementation of HD and bladder training is important in order to achieve long-term remission among IC patients. Hence, HD of the bladder and concomitant bladder training should be recommended as the first treatment choice for patients with IC, once IC is suspected, because it provides significant remission, is a conservative therapy, and avoids extirpative surgeries. References [1] Oravisto KJ. Epidemiology of interstitial cystitis. Ann Chirur Gynaecol Fenn 1975;64:75 e 7. [2] Temml C, Wehrberger C, Riedl C, Ponholzer A, Marszalek M, Madersbacher S. Prevalence and correlates for interstitial cystitis symp- toms in women participating in a health screening project. Eur Urol 2007; 51:803 e 8. [3] O’Leary MP, Sant GR, Fowler Jr FJ, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology 1997; 49:58 e 63. [4] Parsons CL. Interstitial cystitis. In: Ostergard DR, Bent AE, editors. Urogynecology and urodynamics. Theory and practice. 4th ed. Balti- more, MD: Williams &amp; Wilkins; 1996. p. 409 e 25. [5] Propert KJ, Payne C, Kusek JW, Nyberg LM. Pitfalls in the design of clinical trials for interstitial cystitis. Urology 2002;60:742 e 8. [6] French LM, Bhambore N. Interstitial cystitis/painful bladder syndrome. Am Fam Physician 2011;83:1175 e 81. [7] Chaiken DC, Blaivas JG, Blaivas ST. Behavioral therapy for the treat- ment of refractory interstitial cystitis. J Urol 1993;149:1445 e 8. [8] Parsons CL, Koprowski PF. Interstitial cystitis: successful management by increasing urinary voiding intervals. Urology 1991;37:207 e 12. [9] Koziol JA, Clark DC, Gittes RF, Tan EM. The natural history of inter- stitial cystitis: a survey of 374 patients. J Urol 1993;149:465 e 9. [10] Whitmore KE. Self-care regimens for patients with interstitial cystitis. Urol Clin North Am 1994;21:121 e 30. [11] Shorter B, Lesser M, Moldwin RM, Kushner L. Effect of comestibles on symptoms of interstitial cystitis. J Urol 2007;178:145 e 52. [12] Webster DC, Brennan T. Self-care strategies used for acute attack of interstitial cystitis. Urol Nurs 1995;15:86 e 93. [13] Erickson DR, Davies MF. Interstitial cystitis. Int Urogynecol J 1998;9: 174 e 83. [14] Webster DC, Brennan T. Self-care effectiveness and health outcomes in women with interstitial cystitis: implications for mental health clinicians. Iss Ment Health Nurs 1998;19:495 e 519. [15] Rothrock NE, Lutgendorf SK, Kreder KJ, Ratliff T, Zimmerman B. Stress and symptoms in patients with interstitial cystitis: a life stress mode. Urology 2001;57:422 e 7. [16] Weiss JM. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency e frequency syndrome. J Urol 2001; 166:2226 e 31. [17] Markwell SJ. Physical therapy management of pelvi/perineal and peri- anal pain syndromes. World J Urol 2001;19:194 e 9. [18] Lukban JC, Whitmore KE. Pelvic floor muscle re-education treatment of the overactive bladder and painful bladder syndrome. Clin Obstet Gynecol 2002;45:273 e 85. [19] Oyama IA, Rejba A, Lukban JC, Fletcher E,  Kellogg-Spadt S, Holzberg AS, et al. Modified Thiele massage as therapeutic intervention for female patients with interstitial cystitis and high-tone pelvic floor dysfunction. Urology 2004;64:862 e 5. [20] Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, FitzGerald MP, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 2011;185:2162 e 70. [21] Parsons CL, Boychuk D, Jones S, Hurst R, Callahan H. Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol 1990;143: 139 e 42. [22] Parsons CL, Mulholland SG. Successful therapy of interstitial cystitis with pentosanpolysulfate. J Urol 1987;138:513 e 6. [23] Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. Urology 1990;35:552 e 8. [24] Holm-Bentzen M, Jacobsen F, Nerstrøm B, Lose G, Kristensen JK, Pedersen RH, et al. A prospective double-blind clinically controlled multicente r trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J Urol 1987;138: 503 e 7. [25] Parsons CL. Current strategies for managing interstitial cystitis. Expert Opin Pharmacother 2004;5:287 e 93. [26] Parsons CL, Schmidt JD, Pollen JJ. Successful treatment of interstitial cystitis with sodium pentosanpolysulfate. J Urol 1983;130:51 e 3. [27] Fritjofsson A, Fall M, Juhlin R, Persson BE, Ruutu M. Treatment of ulcer and nonulcer interstitial  cystitis with sodium pentosanpolysulfate: a multicenter trial. J Urol 1987;138:508 e 12. [28] Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol 1993; 150:845 e 8. [29] van Ophoven A, Pokupic S, Heineke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol 2004;172:533 e 6. [30] Giannantoni A, Bini V, Dmochowski R, Hanno P, Nickel JC, Proietti S, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol 2012;61:29 e 53. [31] Hertle L, van Ophoven A. Long-term results of amitriptyline treatment for interstitial cystitis. Aktuelle Urol 2010;41(Suppl. 1):S61 e 5. [32] Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol 2003;170:810 e 5. 530 C.-H. Hsieh et al. / Taiwanese Journal of Obstetrics &amp; Gynecology 51 (2012) 526 e 532 </p>
                                        
                                            <p>6. [33] Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immuno- pharmacology 2000;47:119 e 25. [34] Krishnaswamy G, Kelley J, Johnson D, Youngberg G, Stone W, Huang SK, et al. The human mast cell: functions in physiology and disease. Front Biosci 2001;6:1109 e 27. [35] Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol 2004; 171:2138 e 41. [36] Sairanen J, Tammela TL, Leppilahti M, Multanen M, Paananen I, Lehtoranta K, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol 2005;174:2235 e 8. [37] Warren JW, Horne LM, Jebel JR, Marvel RP, Keay SK, Chai TC. Pilot study of sequential oral antibiotics for the treatment of interstitial cystitis. J Urol 2000;163:1685 e 8. [38] Dawson TE, Jamison J. Intravesical treatments for painful bladder syndrome/interstitial  cystitis.  Cochrane  Database  Syst  Rev  2007 (4):CD006113. [39] Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol 1988;140:36 e 9. [40] Rossberger J, Fall M, Peeker R. Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis: discomfort, side-effects and treatment outcome. Scand J Nephrol 2005;39:73 e 7. [41] Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of interstitial cystitis with intravesical heparin. Br J Urol 1994;73:504 e 7. [42] Kallestrup EB, Jorgensen SS, Nordling J, Hald T. Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol 2005;39:143 e 7. [43] Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME. Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol 2007;51: 1534 e 40. [44] Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pfluger H. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J 2008;19:717 e 21. [45] Van Agt S, Gobet F, Sibert L, Leroi AM, Grise P. Treatment of interstitial cystitis by intravesical instillation of hyaluronic acid: a prospective study on 31 patients. Prog Urol 2011;21:218 e 25. [46] Asklin B, Cassuto J. Intravesical lidocaine in severe interstitial cystitis: case report. Scand J Urol Nephrol 1989;23:311 e 2. [47] Rosamilia A, Dwyer PL, Gibson J. Electromotive drug administration of lidocaine and dexamethasone followed by cystodistension in women with interstitial cystitis. Int Urogynecol J 1997;8:142 e 5. [48] Gurpinar T, Wong HY, Griffith DP. Electromotive administration of intravesical lidocaine in patients with interstitial cystitis. J Endourol 1996;10:443 e 7. [49] Sant GR, LaRock DR. Standard intravesical therapies for interstitial cystitis. Urol Clin North Am 1994;21:73 e 83. [50] Davis EL, El Khoudary SR, Talbott EO, Davis J, Regan LJ. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J Urol 2008;179:177 e 85. [51] Barbalias GA, Liatsikos EN, Athanasopoulos A, Nikiforidis G. Intersti- tial cystitis: bladder training with intravesical oxybutynin. J Urol 2000; 163:1818 e 22. [52] Madersbacher H, van Ophoven A, van Kerrebroeck PE. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans d a review. Neurourol Urodyn 2012. http:// dx.doi.org/10.1002/nau.22256 . [53] Swift SE, Chai TC, Bent AE. Painful conditions of the lower urinary tract including painful bladder syndrome. In: Bent AE, Cundiff GW, Swift SE, editors. OSTERGARD’S urogynecology and pelvic floor dysfunction. 6th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2008. p. 106 e 32. [54] Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, et al. Interstitial Cystitis Clinical Trials Group. A randomized controlled trial of intravesical bacillus Calmette e Guerin for 12 treatment refractory interstitial cystitis. J Urol 2005;173:1186 e 91. [55] Payne CK, Mosbaugh PG, Forrest JB, Evans RJ, Whitmore KE, Antoci JP, et al. Intravesical resiniferatoxin for the treatment of inter- stitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol 2005;173:1590 e 4. [56] Keay S, Kaczmarek P, Zhang CO, Koch K, Szekely Z, Barchi Jr JJ, et al. Normalization of proliferation and tight junction formation in bladder epithelial cells from patients with interstitial cystitis/painful bladder syndrome by D-proline and D-pipecolic acid derivatives of anti- proliferative factor. Chem Biol Drug Des 2011;77:421 e 30. [57] Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2010;58:360 e 5. [58] Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 2004;64:871 e 5. [59] Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 2006;49:704 e 9. [60] Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydro- distension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007;70:463 e 8. [61] Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year follow up. J Urol 2008;179:1031 e 4. [62] de Miquel F, Chancellor MB. Pittsburgh experience with botulinum toxin A injection. Actas Urol Esp 2006;30:310 e 4. [63] Tirumuru S, Al-Kurdi D, Latthe P. Intravesical botulinum toxin A injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review. Int Urogynecol J 2010;21:1285 e 300. [64] Bumpus HJ. Interstitial cystitis: its treatment by over-distention of the bladder. Med Clin North Am 1930;13:1495 e 8. [65] Hanno PM, Wein AJ. Conservative therapy of interstitial cystitis. Semin Urol 1991;9:143 e 7. [66] Yamada T, Murayama T, Andoh M. Adjuvant hydrodistension under epidural anesthesia for interstitial cystitis. Int J Urol 2003;10:463 e 8. [67] Tomoe H, Kobayashi H, Nakazawa H, Toma H. The efficacy of hydro- distention of the bladder for interstitial cystitis. J Interst Cyst 2004;2: 24 e 31. [68] Parsons M, Toozs-Hobson P. The investigation and management of interstitial cystitis. J Br Menopause Soc 2005;11:132 e 9. [69] Ottem DP, Teichman JMH. What is the value of cystoscopy with hydrodistension for interstitial cystitis? Urology 2005;66:494 e 9. [70] McCahy PJ, Styles RA. Prolonged bladder distention: experience in the treatment of detrusor overactivity and interstitial cystitis. Eur Urol 1995; 28:325 e 7. [71] Glemain P, Riviere C, Lenormand L, Karam G, Bouchot O, Buzelin JM. Prolonged hydrodistention of the bladder for symptomatic treatment of interstitial cystitis: efficacy at 6 months and 1 year. Eur Urol 2002;41: 79 e 84. [72] Hsieh CH, Chang ST, Hsieh CJ, Hsu CS, Kuo TC, Chang HC, et al. Treatment of interstitial cystitis with hydrodistention and bladder training. Int Urogynecol J 2008;19:1379 e 84. [73] Maher CF, Carey MP, Dwyer PL, Schluter PL. Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis. J Urol 2001;165: 884 e 6. [74] Peters KM. Neuromodulation for the treatment of refractory interstitial cystitis. Rev Urol 2002;4:S36 e 43. [75] Gajewski JB, Al-Zahrani AA. The long-term efficacy of sacral neuro- mo dulation in the management of intractable cases of bladder pain syndrome: 14 yearsofexperienceinone centre.BJUInt 2011;107:1258 e 64. [76] Ghazwani YQ, Elkelini MS, Hassouna MM. Efficacy of sacral neuro- modulation in treatment of bladder pain syndrome: long-term follow-up. Neurourol Urodyn 2011;30:1271 e 5. [77] Shanberg AM, Baghdassarian R, Tansey LA. Treatment of interstitial cystitis with neodymium e YAG laser. J Urol 1985;134:885 e 8. [78] Rofeim O, Hom D, Freid RM, Moldwin RM. Use of the neo- dymium:YAG laser for interstitial cystitis: a prospective study. J Urol 2001;166:134 e 6. 531 C.-H. Hsieh et al. / Taiwanese Journal of Obstetrics &amp; Gynecology 51 (2012) 526 e 532 </p>
                                        
                                            <p></p>
                                        
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="statistic" slide-url="treatment-of-interstitial-cystitis-in-women-49.html">
                                    <div class="row">
                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Nézetek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1190</span>
                                                    <i class="fa fa-play"></i> Total Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">891</span>
                                                    <i class="fa fa-circle-o"></i> Website Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">299</span>
                                                    <i class="fa fa-code"></i> Embedded Views
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Műveletek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="total-share">0</span>
                                                    <i class="fa fa-share-alt"></i> Social Shares
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-up"></i> Likes
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-down"></i> Nemkedvelések
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-comments-o"></i> Comments
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Share count</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="facebook-badge">0</span>
                                                    <i class="fa fa-facebook-square"></i> Facebook
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="twitter-badge">0</span>
                                                    <i class="fa fa-twitter-square"></i> Twitter
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="linkedin-badge">0</span>
                                                    <i class="fa fa-linkedin-square"></i> LinkedIn
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="google-badge">0</span>
                                                    <i class="fa fa-google-plus-square"></i> Google+
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                    <div class="row">
                                        <div class="col-lg-12">
                                            <h4 class="mt0"> Embeds
                                                <span class="badge badge-pill float-right">
                                                    3
                                                </span>
                                            </h4>
                                            <ul class="list-group" style="height: 150px;overflow: auto;">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">5</span>
                                                    www.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">15</span>
                                                    hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    odoo.hbs.hu
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-xl-4 col-lg-4 col-md-12 col-12">
                    <ul class="nav nav-tabs" role="tablist">
                        <li class="nav-item"><a aria-controls="related" href="#related" class="nav-link active" data-toggle="tab">Kapcsolódó</a></li>
                        <li class="nav-item"><a aria-controls="most_viewed" href="#most_viewed" class="nav-link" data-toggle="tab">Most Viewed</a></li>
                    </ul>
                    <div class="tab-content">
                        <div role="tabpanel" id="related" class="tab-pane active mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1504 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/19/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html"><h6 class="mb-1">Cikk a Neurourology and Urodynamics-ban 2018.</h6></a>
            <small class="text-muted">
                1473 Views . <timeago class="timeago" datetime="2019-10-31 13:28:23.618732"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1498 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-diagnostic-algorhytm-21.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/21/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-diagnostic-algorhytm-21.html"><h6 class="mb-1">IC-BPS diagnostic algorhytm.</h6></a>
            <small class="text-muted">
                1488 Views . <timeago class="timeago" datetime="2019-10-31 13:29:57.450898"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="glycosaminoglycan-therapy-for-bladder-diseases-22.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/22/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="glycosaminoglycan-therapy-for-bladder-diseases-22.html"><h6 class="mb-1">Glycosaminoglycan Therapy for Bladder Diseases</h6></a>
            <small class="text-muted">
                1385 Views . <timeago class="timeago" datetime="2019-10-31 13:30:10.980936"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="essic-2017-budapest-abstracts-23.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/23/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="essic-2017-budapest-abstracts-23.html"><h6 class="mb-1">ESSIC 2017 Budapest abstracts</h6></a>
            <small class="text-muted">
                1464 Views . <timeago class="timeago" datetime="2019-10-31 13:30:38.129948"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/24/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html"><h6 class="mb-1">Prevalence of Symptoms of Bladder Pain Syndrome 2011</h6></a>
            <small class="text-muted">
                1304 Views . <timeago class="timeago" datetime="2019-10-31 13:30:57.131521"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/25/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html"><h6 class="mb-1">The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. 2017</h6></a>
            <small class="text-muted">
                1362 Views . <timeago class="timeago" datetime="2019-10-31 13:35:55.689470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/26/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"><h6 class="mb-1">Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016</h6></a>
            <small class="text-muted">
                1299 Views . <timeago class="timeago" datetime="2019-10-31 13:36:14.959707"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/27/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html"><h6 class="mb-1">PENTOSAN POLYSULFATE SODIUM FOR THERAPY of IC Urology 1990</h6></a>
            <small class="text-muted">
                1414 Views . <timeago class="timeago" datetime="2019-10-31 13:37:27.415502"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/28/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html"><h6 class="mb-1">Interstitial cystitis intravesical therapy tau-06-S2-S171 2017</h6></a>
            <small class="text-muted">
                1368 Views . <timeago class="timeago" datetime="2019-10-31 13:38:04.204366"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/29/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html"><h6 class="mb-1">Novel targeted bladder drug-delivery systems rru-7-169 2015</h6></a>
            <small class="text-muted">
                1489 Views . <timeago class="timeago" datetime="2019-10-31 13:38:18.425299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/30/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1221 Views . <timeago class="timeago" datetime="2019-10-31 13:38:52.835202"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/31/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"><h6 class="mb-1">Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721</h6></a>
            <small class="text-muted">
                1388 Views . <timeago class="timeago" datetime="2019-10-31 13:39:08.628954"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/32/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"><h6 class="mb-1">IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638</h6></a>
            <small class="text-muted">
                1251 Views . <timeago class="timeago" datetime="2019-10-31 13:39:22.993300"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/33/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"><h6 class="mb-1">Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology</h6></a>
            <small class="text-muted">
                1389 Views . <timeago class="timeago" datetime="2019-10-31 13:40:52.836690"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/34/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html"><h6 class="mb-1">Hyaluronic Acid and Its Composites as a Local Antimicrobial-Antiadhesive Barrier 2017.jbjiv02p0063</h6></a>
            <small class="text-muted">
                1311 Views . <timeago class="timeago" datetime="2019-10-31 13:45:41.648470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/35/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"><h6 class="mb-1">Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157</h6></a>
            <small class="text-muted">
                1301 Views . <timeago class="timeago" datetime="2019-10-31 13:45:59.326213"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/36/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html"><h6 class="mb-1">Intravesical Glycosaminoglycan Replacement with Chondroitin_2015_Article_306</h6></a>
            <small class="text-muted">
                1359 Views . <timeago class="timeago" datetime="2019-10-31 13:46:19.773972"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                        <div role="tabpanel" id="most_viewed" class="tab-pane  mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="sugarvedo-ruhazat-ismerteto-3.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/3/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="sugarvedo-ruhazat-ismerteto-3.html"><h6 class="mb-1">Sugárvédő ruházat ismertető</h6></a>
            <small class="text-muted">
                3284 Views . <timeago class="timeago" datetime="2018-10-20 14:31:25.547995"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="op-set-system-5.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/5/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="op-set-system-5.html"><h6 class="mb-1">OP Set System</h6></a>
            <small class="text-muted">
                3044 Views . <timeago class="timeago" datetime="2018-11-16 13:38:03.543744"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kompresszios-polya-felhelyezese-8.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/8/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kompresszios-polya-felhelyezese-8.html"><h6 class="mb-1">Kompressziós pólya felhelyezése</h6></a>
            <small class="text-muted">
                2846 Views . <timeago class="timeago" datetime="2018-11-16 13:39:25.884480"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kotszer-polya-l-r-6.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/6/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kotszer-polya-l-r-6.html"><h6 class="mb-1">Kötszer Pólya L&amp;R</h6></a>
            <small class="text-muted">
                2643 Views . <timeago class="timeago" datetime="2018-11-16 13:38:35.611223"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="nedves-sebkezeles-flyer-l-r-7.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/7/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="nedves-sebkezeles-flyer-l-r-7.html"><h6 class="mb-1">Nedves sebkezelés flyer L&amp;R</h6></a>
            <small class="text-muted">
                2438 Views . <timeago class="timeago" datetime="2018-11-16 13:38:59.835920"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-liner-10.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/10/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-liner-10.html"><h6 class="mb-1">PDB_Actico UlcerSys Liner</h6></a>
            <small class="text-muted">
                2324 Views . <timeago class="timeago" datetime="2018-11-16 13:39:54.728282"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-2.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/2/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-2.html"><h6 class="mb-1">SciCan STATIM G4</h6></a>
            <small class="text-muted">
                2321 Views . <timeago class="timeago" datetime="2018-10-20 14:10:02.671163"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-9.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/9/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-9.html"><h6 class="mb-1">PDB_Actico UlcerSys</h6></a>
            <small class="text-muted">
                2209 Views . <timeago class="timeago" datetime="2018-11-16 13:39:42.488113"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-hasznalati-utmutato-v1-1-12.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/12/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-hasznalati-utmutato-v1-1-12.html"><h6 class="mb-1">UroStill_hasznalati_utmutato_v1.1</h6></a>
            <small class="text-muted">
                2038 Views . <timeago class="timeago" datetime="2019-10-31 13:22:24.531510"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="koronavirus-jarvany-61.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/61/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="koronavirus-jarvany-61.html"><h6 class="mb-1">KORONAVIRUS JARVANY</h6></a>
            <small class="text-muted">
                1774 Views . <timeago class="timeago" datetime="2020-04-09 15:16:22.317496"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-1.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/1/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-1.html"><h6 class="mb-1">SciCan Statim G4</h6></a>
            <small class="text-muted">
                1709 Views . <timeago class="timeago" datetime="2018-10-20 14:09:31.661802"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="new-aiding-device-for-self-instillation-v2-16.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/16/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="new-aiding-device-for-self-instillation-v2-16.html"><h6 class="mb-1">New_aiding_device_for_self-instillation_v2</h6></a>
            <small class="text-muted">
                1690 Views . <timeago class="timeago" datetime="2019-10-31 13:23:48.863175"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kitpack-11.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/11/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="kitpack-11.html"><h6 class="mb-1">Kitpack</h6></a>
            <small class="text-muted">
                1684 Views . <timeago class="timeago" datetime="2018-11-16 14:52:39.736537"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="icbps-szoszedet-14.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/14/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="icbps-szoszedet-14.html"><h6 class="mb-1">ICBPS_SZÓSZEDET</h6></a>
            <small class="text-muted">
                1620 Views . <timeago class="timeago" datetime="2019-10-31 13:23:06.826135"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/15/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html"><h6 class="mb-1">IC - FAQ-s and appropriate answers Mumbai 2019</h6></a>
            <small class="text-muted">
                1612 Views . <timeago class="timeago" datetime="2019-10-31 13:23:19.219912"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-users-manual-v1-1-13.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/13/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-users-manual-v1-1-13.html"><h6 class="mb-1">UroStill_Users_Manual_v1.1</h6></a>
            <small class="text-muted">
                1605 Views . <timeago class="timeago" datetime="2019-10-31 13:22:47.677753"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="l-r-corporate-film-4.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/4/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="l-r-corporate-film-4.html"><h6 class="mb-1">L&amp;R Corporate Film</h6></a>
            <small class="text-muted">
                1601 Views . <timeago class="timeago" datetime="2018-11-14 15:53:51.760680"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1504 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1498 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    
                </main>
                <footer class="bg-light o_footer">
                    <div id="footer" class="oe_structure oe_structure_solo">
      <section class="s_text_block pb8 pt40">
        <div class="container">
          <div class="row" style="border-top: solid 1px #ddd; padding-top: 30px;">
            <div class="col-lg-4">
              <h5>További tartalmak</h5>
              <ul class="list-unstyled">
                <li>
                  <a href="../../blog/hirek-esemenyek-1.html" data-original-title="" title="" aria-describedby="tooltip310735">Blog</a>
                  <br/>
                  <a href="../../adatkezelesi-tajekoztato.html">Adatkezelési tájékoztató</a>
                </li>
                <li>
                  <br/>
                </li>
              </ul>
            </div>
            <div class="col-lg-4" id="connect">
              <h5>Elérhetőségek</h5>
              <ul class="list-unstyled">
                <li>
                  <i class="fa fa-phone"></i>
                  <span data-note-id="2">+36 1 452 1700</span>
                </li>
                <li>
                  <i class="fa fa-envelope"></i>
                  <span><a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="5b32353d341b33392875332e">[email&#160;protected]</a></span>
                </li>
              </ul>
              <p> </p>
            </div>
            <div class="col-lg-4">
              <h5>
                <span>HBS Medical</span>
                <small> – <a href="../../aboutus.html" data-original-title="" title="" aria-describedby="tooltip425138">Kapcsolat</a></small>
              </h5>
              <p>&nbsp;<br/></p>
            </div>
          </div>
        </div>
      </section>
    </div>
  <div class="o_footer_copyright">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6 text-muted text-center text-md-left">
                        <span>Copyright &copy;</span> <span itemprop="name">HBS Medical</span>
                        
    

                    </div>
                    <div class="col-lg-6 text-right o_not_editable">
                        
    <div class="o_brand_promotion text-muted">
        Az oldalt készítette:
        <a href="https://eyssen.hu/" target="_blank"><img src="../../web/image/606/eyssen_logo_blue.png" width="120"/></a>
    </div>

                    </div>
                </div>
            </div>
        </div>
    </footer>
            </div>
        <script data-cfasync="false" src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script id="tracking_code">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

            ga('create', _.str.trim('UA-52898474-1'), 'auto');
            ga('send','pageview');
        </script>
    
        
            </body>
        
<!-- Mirrored from hbs.hu/slides/slide/treatment-of-interstitial-cystitis-in-women-49 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:22:30 GMT -->
</html>
    
    
